全文获取类型
收费全文 | 23633篇 |
免费 | 1096篇 |
国内免费 | 688篇 |
专业分类
耳鼻咽喉 | 124篇 |
儿科学 | 775篇 |
妇产科学 | 307篇 |
基础医学 | 1780篇 |
口腔科学 | 106篇 |
临床医学 | 2848篇 |
内科学 | 3074篇 |
皮肤病学 | 192篇 |
神经病学 | 328篇 |
特种医学 | 1323篇 |
外科学 | 6391篇 |
综合类 | 3460篇 |
预防医学 | 877篇 |
眼科学 | 88篇 |
药学 | 2069篇 |
12篇 | |
中国医学 | 798篇 |
肿瘤学 | 865篇 |
出版年
2023年 | 250篇 |
2022年 | 527篇 |
2021年 | 750篇 |
2020年 | 727篇 |
2019年 | 727篇 |
2018年 | 777篇 |
2017年 | 667篇 |
2016年 | 681篇 |
2015年 | 741篇 |
2014年 | 1554篇 |
2013年 | 1462篇 |
2012年 | 1379篇 |
2011年 | 1397篇 |
2010年 | 1118篇 |
2009年 | 1253篇 |
2008年 | 1245篇 |
2007年 | 1222篇 |
2006年 | 1062篇 |
2005年 | 962篇 |
2004年 | 717篇 |
2003年 | 638篇 |
2002年 | 494篇 |
2001年 | 493篇 |
2000年 | 448篇 |
1999年 | 337篇 |
1998年 | 326篇 |
1997年 | 269篇 |
1996年 | 264篇 |
1995年 | 286篇 |
1994年 | 282篇 |
1993年 | 212篇 |
1992年 | 248篇 |
1991年 | 199篇 |
1990年 | 172篇 |
1989年 | 148篇 |
1988年 | 191篇 |
1987年 | 132篇 |
1986年 | 95篇 |
1985年 | 99篇 |
1984年 | 104篇 |
1983年 | 51篇 |
1982年 | 96篇 |
1981年 | 86篇 |
1980年 | 98篇 |
1979年 | 78篇 |
1978年 | 56篇 |
1977年 | 60篇 |
1976年 | 56篇 |
1975年 | 33篇 |
1973年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 14 毫秒
1.
2.
3.
4.
《Revista portuguesa de cardiologia》2022,41(4):311-320
Aims and objectivesVitamin D deficiency is a common finding and there is a suggested association with hypertension. Resistant hypertension is a clinical problem observed in 5–30% of hypertensive patients. Renal denervation (RDN) has been used for patients with resistant hypertension and has proven to lower blood pressure. Our primary goal was to assess the vitamin D serum concentration as a predictor of blood pressure response to RDN in highly selected patients.MethodsThis prospective, nonrandomized, single-center study included 24 patients treated with RDN. Based on their one-year response after RDN, patients were classified as responders or non-responders at six months or at 12 months.ResultsThe median follow-up was 52 months (range, 14-91 months). After RDN, 17 patients (70.8%) had a reduction >5 mmHg in the mean systolic blood pressure, at the first six months of follow-up. At 12 months, 20 patients (83.3%) were responders. Vitamin D levels at baseline (15.1±4.8 vs. 24.2±8.8 ng/ml) and at six months (16.6±7.2 vs. 25±9.2 ng/ml) were lower in early non-responders compared to early responders (p=0.008), without significant variation during follow-up. Even though Vitamin D levels were lower in the total responder's group, no statistically significant differences were found (p=ns).ConclusionIn patients with resistant hypertension, low vitamin D concentrations were associated with an absence of early response to RDN. 相似文献
5.
6.
7.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
8.
9.
10.
目的:探讨上尿路梗阻引起肾功能衰竭的诊断和治疗。方法:回顾分析30例上尿路梗阻引起肾功能衰竭患者的临床资料。结果:梗阻原因肾盂输尿管结石76.67%(23/30),肿瘤10%(3/30),其它13.33%(4/30)。治愈86.67%(26/30),好转13.33%(4/30)。结论:上尿路梗阻引起肾功能衰竭是泌尿外科的急重症,尽早解除梗阻有利于肾功能的恢复。 相似文献